drugset
drugset / Trial / NCT03859219

A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants

NCT03859219 ↗

Phase 1 Completed 65 enrolled UCB Biopharma S.P.R.L.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of the study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of rozanolixizumab in japanese, chinese and caucasian healthy-volunteer study participants.

Timeline

Start
2019-03-18
Primary completion
2020-04-28
Completion
2020-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Rozanolixizumab Monoclonal antibody — Subcutaneous

Indications

No indication recorded.